The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Emerging role of liquid biopsies in lung cancer
Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of liquid biopsies in the detection and diagnosis of non-small cell lung cancer (NSCLC). Liquid biopsies represent a non-invasive approach to characterizing the tumor molecular profile for diagnosis, personalized treatment approaches, as well as understanding mechanisms of resistance that may represent therapeutic targets. Dr Li also outlines the use of liquid biopsies for disease monitoring to understand dynamic changes of genetic clones of cancer in response to treatment. Finally, Dr Li explores the potential of circulating tumor DNA for cancer screening to reduce overall cancer mortality. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
